adamantane has been researched along with glucagon-like peptide 1 in 150 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 59 (39.33) | 29.6817 |
| 2010's | 89 (59.33) | 24.3611 |
| 2020's | 2 (1.33) | 2.80 |
| Authors | Studies |
|---|---|
| Balkan, B; Bolognese, L; Burkey, BF; Hughes, TE; Li, X; Mone, M; Russell, M; Wang, PR | 1 |
| Erlich, R | 1 |
| Berenbeim, DM; Gilkin, RJ; Gleeson, JM | 1 |
| Edwards, CM | 1 |
| Edelman, SV | 1 |
| Dunning, BE; Foley, JE; Mänttäri, S; Matikainen, N; Mills, D; Schweizer, A; Taskinen, MR; Ulvestad, A | 1 |
| Jago, C | 1 |
| Inoue, T; Kira, K; Nagakura, T; Saeki, T; Shinoda, M; Tanaka, I; Yamazaki, K; Yasuda, N | 1 |
| Choukem, SP; Gautier, JF | 1 |
| Drucker, DJ; Nauck, MA | 1 |
| Bailey, CJ; Flatt, PR; Green, BD | 1 |
| Golozoubova, V; Gotfredsen, CF; Knudsen, LB; Raun, K; Rolin, B; von Voss, P | 1 |
| Foley, JE; He, YL; Horowitz, A; Ligueros-Saylan, M; Sallas, W; Watson, CE | 1 |
| Winkler, G | 1 |
| Pratley, RE; Salsali, A | 1 |
| Bullock, JM; Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Wang, Y | 1 |
| Helms, K; Kleppinger, EL | 1 |
| Ahrén, B; Burkey, B; Hughes, TE; Sundler, F; Wierup, N; Winzell, MS | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Scheen, AJ | 1 |
| Campestrini, J; Deacon, CF; He, YL; Holst, JJ; Ligueros-Saylan, M; Nielsen, JC; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y | 1 |
| Amori, RE; Lau, J; Pittas, AG | 1 |
| Jennings, HR; Langley, AK; Suffoletta, TJ | 1 |
| El-Ouaghlidi, A; Foley, J; Holmes, D; Holst, JJ; Nauck, MA; Rehring, E; Schweizer, A | 1 |
| Baron, MA; Deacon, CF; Foley, JE; Holst, JJ; Landin-Olsson, M; Rendell, M; Rochotte, E; Rosenstock, J | 1 |
| Azuma, K; Cobelli, C; Dalla Man, C; Deacon, CF; Foley, JE; He, Y; Holst, JJ; Kangani, C; Kelley, DE; Ligueros-Saylan, M; Mancino, J; Rádiková, Z; Serra, D; Thomas, E; Toledo, FG | 1 |
| Ahrén, B | 4 |
| Ahrén, B; Foley, JE | 1 |
| Bock, G; Burton, DB; Camilleri, M; Deacon, CF; Foley, JE; Giesler, PD; Rizza, RA; Saylan, ML; Serra, DB; Vella, A | 1 |
| Mikhail, N | 1 |
| Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Kelley, DE; Leone-Jones, A; Ligueros-Saylan, M; Yu, T | 1 |
| Pei, Z | 1 |
| Doupis, J; Veves, A | 1 |
| Davidson, JA; Gross, JL; Parente, EB | 1 |
| Cherrington, AD; Duttaroy, A; Edgerton, DS; Hobbs, CH; Johnson, KM; Neal, DW; Scott, M; Zhang, X | 1 |
| Faust, M; Matthes, J | 1 |
| Fonseca, VA; John-Kalarickal, J; Wani, JH | 1 |
| D'Alessio, DA; Denney, AM; Dunning, BE; Foley, JE; He, Y; Hermiller, LM; Martin, JM; Pratley, RE; Prigeon, RL; Saylan, ML; Tharp, WG | 1 |
| Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E | 1 |
| Boehnke, J; Boschmann, M; Budziarek, P; Dobberstein, K; Engeli, S; Foley, JE; He, Y; Jordan, J; Luft, FC; Strauss, A; Sweep, FC | 1 |
| Ahrén, B; Dejager, S; Dunning, BE; Foley, JE; Nilsson, PM; Persson, M; Schweizer, A | 1 |
| Siddiqui, NI | 1 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Nicolucci, A; Rossi, MC | 1 |
| Barnett, AH; Piya, MK; Tahrani, AA | 2 |
| Mathieu, C | 1 |
| Gallwitz, B | 2 |
| Deacon, CF; Holst, JJ | 1 |
| Miuchi, M; Miyagawa, J; Nanba, M | 1 |
| Gallwitz, B; Thornberry, NA | 1 |
| Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA | 1 |
| Freeman, JS | 1 |
| Bodvarsdottir, TB; Gotfredsen, CF; Heller, RS; Karlsen, AE; Knudsen, LB; Vedtofte, L | 1 |
| Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H | 1 |
| Baek, HS; Jin, HY; Liu, WJ; Park, JH; Park, TS | 1 |
| Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S | 1 |
| Cefalu, WT | 1 |
| Buikema, H; de Boer, RA; Oeseburg, H; Silljé, HH; van der Harst, P; van Gilst, WH | 1 |
| Guerci, B; Halter, C | 1 |
| Unger, J | 1 |
| Kuritzky, L | 1 |
| Fakhoury, WK; Lereun, C; Wright, D | 1 |
| Svec, F | 1 |
| Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N | 1 |
| Gerich, J | 1 |
| Garber, AJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| He, YL; Ito, H; Sekiguchi, K; Terao, S; Yamaguchi, M | 1 |
| Boudes, P; Viereck, C | 1 |
| Jellinger, PS | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Seino, Y | 1 |
| Ahrén, B; Dejager, S; Dunning, BE; Foley, JE; Schweizer, A; Villhauer, EB | 1 |
| Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R | 1 |
| Deacon, CF; Hjøllund, KR; Holst, JJ | 1 |
| Schneider, SH; Stamataros, G | 1 |
| Kalra, S | 1 |
| Fonseca, VA | 1 |
| Chen, W; Chi, Y; Han, J; Huang, W; Ni, S; Qian, H; Yang, B; Zhang, H; Zhou, J; Zhou, Y | 1 |
| Brock, M; McFarland, MS; Ryals, C | 2 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Bianchi, R; Burkey, B; Cavaletti, G; Cervellini, I; Ghezzi, P; Lauria, G; Oggioni, N; Porretta-Serapiglia, C | 1 |
| Jin, HY; Kim, W; Liu, WJ; Liu, YN; Park, SK; Park, TS; Shao, YM; Xie, SH | 1 |
| Bunck, MC; Diamant, M; Eekhoff, EM; Foley, JE; Heine, RJ; Nijpels, G; Poelma, M; Schweizer, A | 1 |
| Jermendy, G | 1 |
| Hirano, T; Miyazaki, A; Mori, Y; Nagashima, M; Nohtomi, K; Terasaki, M; Watanabe, T | 1 |
| Alexander, CM; Berger, JP; Carr, RD; Katzeff, HL; Thornberry, N; Xu, SS | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| He, YL; Jusko, WJ; Landersdorfer, CB | 1 |
| He, YL; Irie, S; Ito, H; Sekiguchi, K; Shimada, S; Terao, S; Yamaguchi, M | 1 |
| Cao, F; Li, W; Liu, B; Shen, M; Sun, D; Wang, S; Zhang, Z | 1 |
| Dorso, C; Hamann, L; Harstad, E; Kirby, MS; Kopcho, L; Langish, R; Locke, G; Marcinkeviciene, J; Shipkova, P; Wang, A | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Akarte, AS; Gandhi, S; Sole, S; Srinivasan, BP | 1 |
| Inaba, W; Kamata, K; Mizukami, H; Takahashi, K; Tsuboi, K; Yagihashi, S | 2 |
| Asahara, S; Bartolome, A; Etoh, H; Fuchita, M; Hashimoto, N; Hosooka, T; Inoue, H; Kanno, A; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Mieda, Y; Seino, S; Shimizu, S; Takahashi, H; Teruyama, K | 1 |
| Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K | 1 |
| Higashi, Y; Inoue, G; Nakata, H; Ohtomo, Y; Otsu, S; Sugitani, S; Yamaji, S | 1 |
| Barbieri, M; Campitiello, F; Canonico, R; Canonico, S; Carbonara, O; Della Corte, A; Ferraraccio, F; Gualdiero, P; Marfella, R; Padovano, V; Paolisso, G; Paolisso, P; Petrella, A; Petronella, P; Rizzo, MR; Sasso, FC | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pintana, H; Pipatpiboon, N; Pratchayasakul, W | 1 |
| Asakura, M; Asano, Y; Asanuma, H; Ishibashi-Ueda, H; Ito, S; Kitakaze, M; Liao, Y; Min, KD; Minamino, T; Mochizuki, N; Sanada, S; Shindo, K; Takahashi, A; Takashima, S; Yamazaki, S; Yan, Y | 1 |
| Basavan, D; Chinni, S; Dubala, A; Gali, CC; Holsinger, RM; Khatwal, RB; Kosaraju, J; Madhunapantula, VS; Muthureddy Nataraj, SK | 1 |
| Cohen, D | 1 |
| García-Ortega, YE; Gómez-Gaitán, EA; González-Ortiz, LJ; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA; Sánchez-Peña, MJ | 1 |
| Deacon, CF; Hartmann, B; Holst, JJ; Hovendal, C; Knop, FK; Meisner, S; Plamboeck, A; Svendsen, LB; Veedfald, S; Vilsbøll, T; Wettergren, A | 1 |
| Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M | 1 |
| Basavan, D; Chinni, S; Dubala, A; Khatwal, RB; Kosaraju, J; Murthy, V; Muthureddy Nataraj, SK | 1 |
| Begum, SS; Hausenloy, DJ; Mocanu, MM; Riksen, N; Theodorou, L; Whittington, HJ; Wynne, AM; Yellon, DM | 1 |
| Hirota, D; Kajitani, N; Kodera, R; Makino, H; Miyamoto, S; Oda, K; Ono, T; Shikata, K; Takatsuka, T; Usui, HK | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Tibaldi, JM | 1 |
| Bergholm, AM; Brodie, T; Chadwick, KD; Graziano, MJ; LaCerte, C; Mangipudy, RS; Parkes, D; Reilly, TP; Roy, D; Tatarkiewicz, K | 1 |
| Bramlage, P; Forst, T | 1 |
| Ding, M; Li, CJ; Liu, XJ; Yu, DM; Yu, P; Yu, Q; Zhang, QM | 1 |
| Bando, YK; Ishii, M; Kambara, T; Kondo, K; Murohara, T; Nishimura, M; Ouchi, N; Shibata, R; Shimizu, Y; Tanigawa, T | 1 |
| Deacon, CF; Feinle-Bisset, C; Heruc, GA; Horowitz, M; Little, TJ; Luscombe-Marsh, N; Rayner, CK | 1 |
| Birdsey, N; Keller, AC; Klemm, DJ; Knaub, LA; Miller, MW; Reusch, JE | 1 |
| Fujisawa, Y; Kobori, H; Kohno, M; Masaki, T; Mori, H; Nakano, D; Nishiyama, A; Ohmori, K; Rafiq, K; Rahman, A; Sufiun, A | 1 |
| Itoh, T; Kajikuri, J; Komori, K; Koyama, A; Otsuka, R | 1 |
| Deacon, CF; Hansen, M; Hartmann, B; Hjøllund, KR; Holst, JJ; Plamboeck, A; Wewer Albrechtsen, NJ | 1 |
| Jain, R | 1 |
| Baker, WL; White, WB | 1 |
| Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
| Broschag, M; Deacon, CF; Foley, J; He, YL; Holst, JJ; Kind, J; Kjems, L; Köthe, LD; Nauck, MA | 1 |
| Boulton, DW | 1 |
| Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 1 |
| Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Burkey, B; Duttaroy, A; Hu, J; Kawamori, D; Kulkarni, RN; Liew, CW; Morioka, T; Shirakawa, J | 1 |
| Bogdanov, P; García-Ramírez, M; Genís, X; Hernández, C; Sampedro, J; Simó, R; Simó-Servat, O; Solà-Adell, C; Valeri, M | 1 |
| Li, M; Ping, F; Wang, T; Wang, X; Xiao, X; Yu, M; Zhang, Q; Zheng, J | 1 |
| Liu, L; Wang, DW; Wang, K; Wang, P; Wang, W; Wen, Z; Wu, L | 1 |
| Chen, S; Chen, Y; Deng, Y; Fernando, RL; Guo, A; Peng, P; Sun, J; Zhao, G; Zhou, M | 1 |
| Abd El Fattah, MA; Abdallah, DM; El-Abhar, HS; Kamel, NM | 1 |
| Aerts, JMFG; Boot, R; Foppen, E; Herrera Moro Chao, D; Jansen, K; Kalsbeek, A; Kooijman, S; Marques, AR; Mergen, C; Mirzaian, M; Ottenhoff, R; Overkleeft, H; Parlevliet, ET; Rensen, PCN; Scheij, S; Seeley, RJ; Tschöp, MH; van Eijk, M; van Roomen, C; Verhoek, M; Wang, D; Wang, Y; Yi, CX | 1 |
| Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Sun, Z; Wang, X; Wu, T; Xie, C | 1 |
| El-Naga, RN; Gad, AM; Nazeem, M; Wahdan, SA | 1 |
61 review(s) available for adamantane and glucagon-like peptide 1
| Article | Year |
|---|---|
Incretin mimetics: promising new therapeutic options in the treatment of type 2 diabetes.
Topics: Adamantane; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Peptides; Pyrrolidines; Venoms | 2005 |
The GLP-1 system as a therapeutic target.
Topics: Adamantane; Blood Glucose; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Pyrrolidines | 2005 |
Incretins: what does the future hold?
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Exenatide; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peptides; Protease Inhibitors; Pyrrolidines; Venoms; Vildagliptin | 2005 |
How do different GLP-1 mimetics differ in their actions?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin | 2006 |
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2006 |
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycoproteins; Homeostasis; Humans; Hypoglycemic Agents; Islets of Langerhans; Models, Biological; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
The role of vildagliptin in the management of type 2 diabetes mellitus.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastric Emptying; Glucagon-Like Peptide 1; Glucose; Humans; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Liver; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Nitriles; Protein Conformation; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Structure-Activity Relationship; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
DPP4 inhibitors: a new approach in diabetes treatment.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Incretin-based therapies in type 2 diabetes: a review of clinical results.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Drug evaluation: vildagliptin-metformin single-tablet combination.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipids; Metformin; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Safety; Treatment Outcome; Vildagliptin | 2009 |
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Randomized Controlled Trials as Topic; Sex Factors; Time Factors | 2009 |
The scientific evidence: vildagliptin and the benefits of islet enhancement.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
[The value of incretin based therapies].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Topics: Adamantane; Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Safety; Treatment Outcome | 2009 |
[Incretin related agents for treatment of diabetes mellitus].
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
DPP-4 inhibitors in clinical practice.
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
Topics: Adamantane; Amino Acid Sequence; Chemistry, Pharmaceutical; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Molecular Sequence Data; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2010 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss | 2010 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Nitriles; Pyrrolidines; Vildagliptin | 2011 |
Vildagliptin in the treatment of type 2 diabetes mellitus.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Nitriles; Pyrrolidines; Vildagliptin | 2011 |
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Pyrrolidines; Vildagliptin | 2011 |
Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.
Topics: Adamantane; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drugs, Investigational; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Risk Assessment; Risk Reduction Behavior | 2011 |
Place in therapy for liraglutide and saxagliptin for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Incretins; Liraglutide | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Insulin; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents | 2015 |
Cardiovascular Effects of Incretin-Based Therapies.
Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Piperidines; Sitagliptin Phosphate; Uracil | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Topics: Adamantane; Area Under Curve; Cytochrome P-450 CYP3A; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Half-Life; Humans; Hypoglycemic Agents; Metabolic Clearance Rate | 2017 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin | 2017 |
28 trial(s) available for adamantane and glucagon-like peptide 1
| Article | Year |
|---|---|
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
Topics: Adamantane; Apolipoprotein B-48; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Intestinal Mucosa; Intestines; Lipids; Lipoproteins; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Time Factors; Treatment Outcome; Triglycerides; Vildagliptin | 2006 |
Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.
Topics: Adamantane; Adult; Analysis of Variance; Blood Glucose; C-Peptide; Chromatography, Liquid; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Radioimmunoassay; Tandem Mass Spectrometry; Time Factors; Vildagliptin | 2007 |
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Nausea; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Vomiting | 2007 |
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
Topics: Adamantane; Adult; Algorithms; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glyburide; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Topics: Adamantane; Blood Glucose; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Inulin; Kinetics; Male; Nitriles; Placebos; Postprandial Period; Pyrrolidines; Vildagliptin | 2008 |
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Topics: Adamantane; Blood Glucose; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin | 2008 |
The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
Topics: Adamantane; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drinking; Eating; Enteroendocrine Cells; Fasting; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Middle Aged; Nitriles; Organ Size; Placebos; Postprandial Period; Pyrrolidines; Satiation; Stomach; Vildagliptin | 2008 |
Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 1; Feeding Behavior; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Islets of Langerhans; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
Topics: Adamantane; Adipose Tissue; Adult; Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Lipid Mobilization; Male; Middle Aged; Muscle, Skeletal; Nitriles; Norepinephrine; Oxidation-Reduction; Postprandial Period; Pyrrolidines; Vildagliptin | 2009 |
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2010 |
The metabolic syndrome influences the response to incretin-based therapies.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2011 |
Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
Topics: Adamantane; Aged; Alkaline Phosphatase; Biomarkers; Blood Glucose; Bone and Bones; Bone Resorption; Calcium; Collagen Type I; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Homeostasis; Humans; Insulin; Male; Middle Aged; Netherlands; Nitriles; Peptides; Phosphates; Postprandial Period; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin | 2012 |
Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.
Topics: Adamantane; Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Models, Biological; Nitriles; Pyrrolidines; Vildagliptin | 2012 |
Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
Topics: Adamantane; Adult; Analysis of Variance; Area Under Curve; Asian People; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Monitoring; Eating; Feeding Behavior; Female; Food-Drug Interactions; Glucagon-Like Peptide 1; Humans; Intestinal Absorption; Japan; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin | 2012 |
Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Capillaries; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Foot; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gene Expression Regulation; Glucagon-Like Peptide 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Italy; Male; Middle Aged; Neovascularization, Physiologic; Nitriles; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrrolidines; RNA, Messenger; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vildagliptin; Wound Healing | 2012 |
Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
Topics: Adamantane; Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Kinetics; Male; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Vildagliptin | 2013 |
Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.
Topics: Acetaminophen; Adamantane; Aged; Area Under Curve; Case-Control Studies; Dipeptidyl-Peptidase IV Inhibitors; Duodenal Ulcer; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Insulin-Secreting Cells; Male; Nitriles; Pylorus; Pyrrolidines; Vagotomy, Truncal; Vildagliptin | 2013 |
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Topics: Adamantane; Adult; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Topics: Adamantane; Adolescent; Adult; Appetite Regulation; Cross-Over Studies; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Energy Intake; Energy Metabolism; Food-Drug Interactions; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Peptide Fragments; Peptide YY; Postprandial Period; Pyrrolidines; Vildagliptin; Young Adult | 2014 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Healthy Volunteers; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Peptide Fragments; Pyrrolidines; Vildagliptin | 2016 |
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Topics: Adamantane; Aged; Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Exercise Therapy; Feedback, Physiological; Female; Glucagon-Like Peptide 1; Humans; Male; Meals; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin | 2016 |
Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Energy Metabolism; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Insulin; Nitriles; Pyrrolidines; Vildagliptin | 2020 |
61 other study(ies) available for adamantane and glucagon-like peptide 1
| Article | Year |
|---|---|
Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
Topics: Adamantane; Animals; Area Under Curve; Blood Glucose; Dietary Fats; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Oxidase; Glucose Tolerance Test; Insulin Resistance; Male; Nitriles; Pyrrolidines; Rats; Rats, Zucker; Tachyphylaxis; Time Factors; Vildagliptin; Weight Gain | 2005 |
American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Nitriles; Peptide Fragments; Protease Inhibitors; Protein Precursors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin; Xanthines | 2005 |
Molecule of the month. Vildagilptin.
Topics: Adamantane; Diabetes Mellitus; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Resistance; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2006 |
American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.
Topics: Adamantane; Clinical Trials as Topic; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peripheral Vascular Diseases; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Hypoglycemic Agents; Imidazoles; Insulin; Kinetics; Mice; Mice, Inbred C57BL; Nitriles; Piperazines; Protease Inhibitors; Purines; Pyridazines; Pyrrolidines; Rats; Rats, Zucker; Tosyl Compounds; Vildagliptin | 2006 |
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.
Topics: Adamantane; Animals; Body Composition; Body Weight; Candy; Energy Intake; Energy Metabolism; Glucagon-Like Peptide 1; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Pancreas; Pyrrolidines; Rats; Rats, Sprague-Dawley; Vildagliptin | 2007 |
DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Topics: Adamantane; Amyloid; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Islets of Langerhans; Mice; Mice, Transgenic; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
[Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Nitriles; Peptides; Pyrrolidines; Receptors, Glucagon; Treatment Outcome; Venoms; Vildagliptin | 2007 |
Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Topics: Adamantane; Animals; Consciousness; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Liver; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gerbillinae; Glucagon-Like Peptide 1; Immunohistochemistry; Insulin; Liraglutide; Male; Nitriles; Pancreas; Pyrrolidines; Reference Standards; Vildagliptin | 2010 |
Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Eating; Electric Stimulation; Epidermis; Glucagon-Like Peptide 1; Humans; Insulin; Male; Nerve Degeneration; Nitriles; Peripheral Nerves; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Ubiquitin Thiolesterase; Vildagliptin | 2009 |
Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Topics: Adamantane; Animals; Cells, Cultured; Cellular Senescence; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Heme Oxygenase-1; Humans; Hydrogen Peroxide; Hypoglycemic Agents; Male; NAD(P)H Dehydrogenase (Quinone); Nitriles; Oxidants; Oxidative Stress; Peptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrrolidines; Rats; Rats, Zucker; Reactive Oxygen Species; Receptors, Glucagon; Signal Transduction; Venoms; Vildagliptin | 2010 |
[New hypoglycemic agents in type 2 diabetes].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2010 |
Choosing among the incretin agents and why it matters.
Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
Understanding the incretin effect.
Topics: Adamantane; Animals; Blood Glucose; Comprehension; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2011 |
Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.
Topics: Adamantane; Animals; Bombesin; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Nitriles; Peptide Fragments; Portal Vein; Pyrrolidines; Swine; Vildagliptin | 2011 |
Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Drug Combinations; Drug Evaluation, Preclinical; Drug Stability; Glucagon-Like Peptide 1; Glucose Tolerance Test; Half-Life; Hypoglycemic Agents; Male; Mice; Nitriles; Protein Processing, Post-Translational; Proteolysis; Pyrrolidines; Structure-Activity Relationship; Vildagliptin | 2012 |
Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Incretins | 2011 |
Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Topics: Adamantane; Animals; Behavior, Animal; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drinking; Eating; Glucagon-Like Peptide 1; Glucose Tolerance Test; Male; Neural Conduction; Nitriles; Pain Threshold; Peripheral Nervous System Diseases; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Vildagliptin | 2012 |
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adamantane; Animals; Blood Glucose; Body Weight; Caspase 3; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Gene Expression; Glomerular Basement Membrane; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Insulin; Kidney; Male; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Transforming Growth Factor beta1 | 2012 |
Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.
Topics: Adamantane; Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dipeptidyl-Peptidase IV Inhibitors; Foam Cells; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Lipoproteins, LDL; Male; Mice; Nitriles; Plaque, Atherosclerotic; Pyrrolidines; Weight Loss | 2012 |
Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metfo
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines | 2012 |
The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice.
Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Endothelial Cells; Endothelium, Vascular; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; NADPH Oxidases; Oxidative Stress; Pyrrolidines; Receptors, Glucagon; Tetrazoles; Valine; Valsartan; Vascular Cell Adhesion Molecule-1 | 2012 |
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Topics: Adamantane; Algorithms; Animals; Artifacts; Cloning, Molecular; Dipeptidases; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Indicators and Reagents; Kinetics; Macaca fascicularis; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Species Specificity; Triazoles; Vildagliptin | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Blood Proteins; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucose Transporter Type 2; Glucose Transporter Type 4; Glycogen; Hypoglycemic Agents; Inflammation; Insulin; Insulin Secretion; Liver; Muscle, Skeletal; Nitrates; Nitriles; Nitrites; Pancreas; Pyrrolidines; Rats; Rats, Wistar; RNA, Messenger; Tumor Necrosis Factor-alpha | 2012 |
Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adamantane; Animals; Apoptosis; Cell Proliferation; Deoxyguanosine; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Nitriles; Pyrrolidines; Rats; Time Factors; Vildagliptin | 2012 |
DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
Topics: Adamantane; Animals; Blood Glucose; CCAAT-Enhancer-Binding Protein-beta; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endoplasmic Reticulum Stress; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Insulin-Secreting Cells; Leupeptins; Mice; Mice, Transgenic; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin | 2012 |
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin | 2012 |
Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucagon-Like Peptide 1; Humans; Incretins; Kidney Failure, Chronic; Liraglutide; Magnetic Resonance Imaging; Male; Nitriles; Pancreatitis; Pyrrolidines; Renal Dialysis; Tomography, X-Ray Computed; Vildagliptin | 2012 |
DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption.
Topics: Adamantane; Animals; Brain; Cognition; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Glucagon-Like Peptide 1; Insulin Receptor Substrate Proteins; Insulin Resistance; Long-Term Synaptic Depression; Male; Maze Learning; Membrane Potential, Mitochondrial; Memory; Mitochondria; Neurons; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Vildagliptin | 2013 |
Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice.
Topics: Adamantane; Animals; Apoptosis; Blood Pressure; Blotting, Western; Dipeptidyl-Peptidase IV Inhibitors; Electrocardiography; Enzyme-Linked Immunosorbent Assay; Fibrosis; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heart Failure; Heart Rate; Hemodynamics; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Nitriles; Organ Size; Pyrrolidines; Real-Time Polymerase Chain Reaction; Survival; Vildagliptin | 2013 |
Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antibiotics, Antineoplastic; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Exploratory Behavior; Gene Expression Regulation; Glucagon-Like Peptide 1; Hippocampus; Interleukin-1beta; Male; Maze Learning; Rats; Rats, Wistar; Streptozocin; tau Proteins; Tumor Necrosis Factor-alpha | 2013 |
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
The effects of dipeptidyl-peptidase-IV inhibitor, vildagliptin, on the exocrine pancreas in spontaneously diabetic Goto-Kakizaki rats.
Topics: Acinar Cells; Adamantane; Animals; Apoptosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glucagon-Like Peptide 1; Immunohistochemistry; Insulin; Ki-67 Antigen; Male; Nitriles; Pancreas, Exocrine; Pancreatic Ducts; Pyrrolidines; Rats; Rats, Wistar; Species Specificity; Vildagliptin | 2013 |
Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition Disorders; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hippocampus; Hypoglycemic Agents; Interleukin-1beta; Male; Maze Learning; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Streptozocin; tau Proteins; Tumor Necrosis Factor-alpha; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Topics: Adamantane; Animals; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Heart; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitriles; Pyrazines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Glucagon; Severity of Illness Index; Signal Transduction; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon-Like Peptide 1; Kidney Diseases; Kidney Glomerulus; Male; Nitriles; Protective Agents; Pyrrolidines; Rats; Rats, Sprague-Dawley | 2014 |
The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Dipeptides; Dogs; Exenatide; Glucagon-Like Peptide 1; Haplorhini; Injections, Subcutaneous; Maximum Tolerated Dose; Mice; Organ Size; Pancreas; Peptides; Rats; Venoms | 2014 |
Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Adiponectin; Animals; Cell Differentiation; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hindlimb; Human Umbilical Vein Endothelial Cells; Ischemia; Mice; Mice, Knockout; Muscle, Skeletal; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrrolidines; Signal Transduction; Vildagliptin | 2014 |
Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki rat.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon-Like Peptide 1; Mitochondria, Muscle; Mitochondrial Proteins; Motor Activity; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type III; Organelle Biogenesis; Physical Conditioning, Animal; Rats; Treatment Outcome | 2015 |
Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats.
Topics: Adamantane; Animals; Antihypertensive Agents; Arterial Pressure; Blood Pressure; Circadian Rhythm; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Heart Rate; Hypertension; Injections, Intraventricular; Male; Nitriles; Pyrrolidines; Rats; Rats, Inbred Dahl; Sodium; Sodium Chloride, Dietary; Telemetry; Vildagliptin | 2015 |
Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
Topics: Adamantane; Administration, Oral; Animals; Autografts; Calcium; Calcium Signaling; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Hyperplasia; Jugular Veins; Male; Neointima; Nitric Oxide; Nitric Oxide Synthase; Nitriles; Pyrrolidines; Time Factors; Vasodilation; Vasodilator Agents; Vildagliptin | 2016 |
Important species differences regarding lymph contribution to gut hormone responses.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Intestinal Mucosa; Lymph; Nitriles; Pyrrolidines; Species Specificity; Swine; Vildagliptin | 2015 |
Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Topics: Adamantane; Algorithms; Area Under Curve; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.
Topics: Adamantane; Animals; Cell Proliferation; Cyclin A; Cyclin D; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Insulin; Insulin-Secreting Cells; Mice; Mice, Knockout; Nitriles; Peptides; Phosphorylation; Pyrrolidines; Receptor, Insulin; Signal Transduction; Venoms; Vildagliptin | 2017 |
Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Electroretinography; Glucagon-Like Peptide 1; Humans; Immunohistochemistry; Male; Mice; Retina; Sitagliptin Phosphate | 2017 |
Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
Topics: Adamantane; Administration, Oral; Animals; Blood Glucose; Butyrates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Insulin Resistance; Interleukin-6; Male; Nitriles; Pyrrolidines; Random Allocation; Rats, Sprague-Dawley; RNA, Ribosomal, 16S; Vildagliptin | 2017 |
Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR alpha | 2018 |
DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cerebral Cortex; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycosylation; Hippocampus; Humans; Intermediate Filaments; Learning; Memory Disorders; Mice; Mice, Transgenic; Nerve Degeneration; Phosphorylation; Signal Transduction; Sitagliptin Phosphate; tau Proteins | 2019 |
Novel repair mechanisms in a renal ischaemia/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF, ANP/eNOS/NO, SDF-1α/CXCR4, and Kim-1/STAT3/HIF-1α/VEGF/eNOS pathways.
Topics: Adamantane; Animals; Atrial Natriuretic Factor; Cell Adhesion Molecules; Chemokine CXCL12; Cyclic AMP; Dipeptides; Disease Models, Animal; Glucagon-Like Peptide 1; Glutathione; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney; Male; Malondialdehyde; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; Receptors, CXCR4; Reperfusion Injury; Signal Transduction; STAT3 Transcription Factor; Vascular Endothelial Growth Factor A | 2019 |
The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1.
Topics: 1-Deoxynojirimycin; Adamantane; Adipose Tissue, Brown; Animals; Brain; Glucagon-Like Peptide 1; Glucose; Male; Mice; Mice, Inbred C57BL; Obesity; Rats; Rats, Wistar; Satiation; Signal Transduction | 2019 |
Saxagliptin ameliorated the depressive-like behavior induced by chronic unpredictable mild stress in rats: Impact on incretins and AKT/PI3K pathway.
Topics: Adamantane; Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain; Brain-Derived Neurotrophic Factor; Caspase 3; Depression; Dipeptides; Disease Models, Animal; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Incretins; Inflammation; Male; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Stress, Psychological | 2021 |